BPC-157 Side Effects: Severity Distribution by Patient Phenotype

Is there a severity distribution by phenotype?

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. FDA identified five small human studies: enema studies reported in meeting proceedings, a retrospective chart review, a single-arm pilot and a two-person pilot [1]. A separate 2026 systematic review of orthopaedic and regenerative use included three studies with 30 patients total, all of poor methodological quality, with certainty of evidence rated very low [2]. None of the accounts below grades side effects by severity.

What has been reported

FDA's adverse-event database search through December 4, 2025 found three reports, all for injectable BPC-157 [1]. One described injection-site redness and swelling lasting nine days in a patient who also used compounded thymosin [1]. One described shortness of breath leading to an emergency room visit, with no other detail [1]. One described widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product [1]. FDA said it cannot tell whether BPC-157 caused these events [1].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small and gave limited safety information [1]. In the healthy-volunteer enema studies, the most frequent events were headache and flatulence [1]. A 2005 meeting abstract of 53 people with mild to moderate ulcerative colitis randomized to BPC-157 80 mg enemas or placebo daily for two weeks reported no difference in adverse events against placebo [1]. FDA said that abstract has too little detail to judge effectiveness, and no full paper exists [1].

The other studies were also small. A knee-pain chart review covered 17 patients, 16 of whom were reached by phone, with no adverse events noted [3]. A pilot in 12 women with interstitial cystitis injected a total of 10 mg around the bladder wall in one procedure, with no adverse events reported [4]. A two-person intravenous pilot gave 10 mg on day 1 and 20 mg on day 2, with no side effects reported [5]. Two participants cannot establish safety.

Which patient groups have data?

The human reports cover a few groups: healthy volunteers (enema studies and the two-person intravenous pilot), people with mild to moderate ulcerative colitis, people with knee pain, and women with interstitial cystitis who had not responded to pentosan polysulfate [1][3][4][5]. Each was small, and the available accounts give no side-effect rates broken down by subgroup.

FDA's stated concerns about compounded BPC-157 are about product and route rather than a patient subgroup: possible immunogenicity for certain routes of administration, peptide-related impurities, and characterization of the active ingredient. The agency says it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [6].

Animal studies add signals. In 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised ALT, glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1].

Route matters for what is known. FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or skin [1]. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

What the reports can and cannot show

Three spontaneous reports cannot be turned into rates or compared across patient groups [1]. The events were also of different kinds: a local injection-site reaction, a breathing episode, and skin and gum darkening [1].